{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amyloid+Beta-Peptides&page=2",
    "query": {
      "condition": "Amyloid Beta-Peptides",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Amyloid+Beta-Peptides&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T04:49:41.910Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02161458",
      "title": "Escitalopram Effects on CSF Amyloid Beta",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Amyloid Beta Protein"
      ],
      "interventions": [
        {
          "name": "Escitalopram 20mg for 2 weeks",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram 20mg for 8 weeks",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram 30mg for 8 weeks",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 98,
      "start_date": "2014-06",
      "completion_date": "2019-01",
      "has_results": true,
      "last_update_posted_date": "2020-04-09",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02161458"
    },
    {
      "nct_id": "NCT05820932",
      "title": "Predicting Cognitive Decline From Androgen Deprivation Therapy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Blood-based assay",
          "type": "GENETIC"
        },
        {
          "name": "Cognitive assessments",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Quality of Life Surveys",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2023-05-22",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05820932"
    },
    {
      "nct_id": "NCT01020838",
      "title": "Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Florbetaben (BAY94-9172)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lantheus Biosciences Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2009-11",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2016-05-27",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 8,
      "location_summary": "Sun City, Arizona • Stanford, California • Tampa, Florida + 5 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Teaneck",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01020838"
    },
    {
      "nct_id": "NCT01148498",
      "title": "A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "solanezumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 55,
      "start_date": "2010-08",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-09-25",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01148498"
    },
    {
      "nct_id": "NCT06659549",
      "title": "A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy of the Macula"
      ],
      "interventions": [
        {
          "name": "GAL-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galimedix Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2025-01-10",
      "completion_date": "2027-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 3,
      "location_summary": "Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Hagerstown",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06659549"
    },
    {
      "nct_id": "NCT00299988",
      "title": "Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Intravenous Immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2006-02",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2019-12-11",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00299988"
    },
    {
      "nct_id": "NCT00905372",
      "title": "Effect of LY2062430 on the Progression of Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "LY2062430",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2009-05",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2012-09-25",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 59,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tuscon, Arizona + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Carson",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00905372"
    },
    {
      "nct_id": "NCT01217021",
      "title": "Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "[18F] MNI-558",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute for Neurodegenerative Disorders",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2010-09",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2011-07-25",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01217021"
    },
    {
      "nct_id": "NCT05834296",
      "title": "Study in Subjects With Mild-to-Moderate Alzheimer's Dementia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ALZN002 (autologous DCs pulsed with E22W mutant peptide).",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alzamend Neuro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-07-05",
      "completion_date": "2028-03-03",
      "has_results": false,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 1,
      "location_summary": "Doral, Florida",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05834296"
    },
    {
      "nct_id": "NCT00765115",
      "title": "A Study of Healthy Subjects to Assess the Effect of LY450139 on Amyloid Beta Peptide Production Rate and or Dose Response.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "LY450139",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "21 Years to 50 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2006-07",
      "completion_date": "2007-09",
      "has_results": false,
      "last_update_posted_date": "2008-10-02",
      "last_synced_at": "2026-07-24T04:49:41.910Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00765115"
    }
  ]
}